文献速递艾滋病与性传播感染

阿扎那韦与达芦那韦在HIV孕妇中的实验室及临床结局比较

Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

该全国性观察研究纳入500例孕期暴露于阿扎那韦(n=409)或达芦那韦(n=91)的HIV孕妇,评估实验室指标和主要妊娠结局。两组妊娠结局、病毒学抑制及多数实验室指标无差异,但达芦那韦组孕晚期甘油三酯和总胆固醇/HDL比值更高,阿扎那韦组胆红素更高。

要点

  • 阿扎那韦与达芦那韦在孕期的主要妊娠结局和病毒学抑制相似。
  • 达芦那韦组孕晚期甘油三酯及总胆固醇/HDL比值更高。
  • 阿扎那韦组孕晚期胆红素水平更高。

核心结论

  • 两种主要孕期推荐HIV蛋白酶抑制剂在妊娠期安全性和活性相似,主要妊娠结局无差异。

研究设计与样本

  • 全国性观察研究,最终分析纳入500例孕期暴露于阿扎那韦(n=409)或达芦那韦(n=91)的HIV孕妇。

主要发现

  • 两组妊娠结局、孕期体重增加、停药、HIV-RNA检测不到、血红蛋白、ALT、总胆固醇、HDL胆固醇和LDL胆固醇均无差异。
  • 孕晚期达芦那韦组血浆甘油三酯中位数235.5 vs 179 mg/dL(P=0.032),总胆固醇/HDL胆固醇比值中位数4.03 vs 3.27(P=0.028)。
  • 孕晚期阿扎那韦组血浆胆红素中位数1.54 vs 0.32 mg/dL(P<0.001)。

临床怎么用

  • 基于实验室指标的微小差异,处方医生可在血脂和胆红素影响具有临床相关性的特定情况下优先选择其中一种药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atazanavir and darunavir represent the main HIV PIs recommended in pregnancy, but comparative data in pregnant women are limited. We assessed the safety and activity profile of these two drugs in pregnancy using data from a national observational study. METHODS: Women with atazanavir or darunavir exposure in pregnancy were evaluated for laboratory measures and main pregnancy outcomes (e.g. preterm delivery, low birthweight, non-elective caesarean section and neonatal gestational age-adjusted birthweight Z-score). RESULTS: Final analysis included 500 pregnancies with either atazanavir (n = 409) or darunavir (n = 91) exposure. No differences in pregnancy outcomes, weight gain in pregnancy, drug discontinuations, undetectable HIV-RNA, haemoglobin, ALT, total cholesterol, HDL cholesterol and LDL cholesterol were observed between the two groups. At third trimester, exposure to darunavir was associated with higher levels of plasma triglycerides (median 235.5 versus 179 mg/dL; P = 0.032) and a higher total cholesterol/HDL cholesterol ratio (median 4.03 versus 3.27; P = 0.028) and exposure to atazanavir was associated with higher levels of plasma bilirubin (1.54 versus 0.32 mg/dL; P < 0.001). CONCLUSIONS: In this observational study, the two main HIV PIs currently recommended by perinatal guidelines showed similar safety and activity in pregnancy, with no evidence of differences between the two drugs in terms of main pregnancy outcomes. Based on the minor differences observed in laboratory measures, prescribing physicians might prefer either drug in some particular situations where the different impacts of treatment on lipid profile and bilirubin may have clinical relevance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Floridia M, Masuelli G, Ravizza M, et al. Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study. J Antimicrob Chemother. 2018. PMID: 29244115. doi:10.1093/jac/dkx478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。